1. Mean change from baseline in disease and disability outcomes at 6 months for TNFi initiators by anti-CCP status.
Mean change from baseline in disease and disability outcomes at 6 months for TNFi initiators by anti-CCP status. Model adjusted by baseline age, sex, body mass index, CDAI score, comorbidity index, and number of prior biological DMARD. All p values > Anti-CCP status was defined as either anti-CCP− positive (≥ 20 units/ml) or anti-CCP–negative (< 20 units/ml). Patient numbers: unadjusted anti-CCP+, n = 1113; unadjusted anti-CCP−, n = 602; adjusted anti-CCP+, n = 1110; adjusted anti-CCP−, n = 600. Anti-CCP: anticyclic citrullinated peptide antibodies; CDAI: Clinical Disease Activity Index; DMARD: disease-modifying antirheumatic drug; TNFi: tumor necrosis factor-α inhibitor.
Leslie R. Harrold et al. J Rheumatol 2018;45:32-39
©2018 by The Journal of Rheumatology